timothy sykes logo

Stock News

Candel Therapeutics’ Stock Offering Sees Market Reaction

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 2/21/2026, 11:13 am ET 2/21/2026, 11:13 am ET | 4 min 4 min read
Candel Therapeutics’ Stock Offering Sees Market Reaction Thumbnail

Candel Therapeutics Inc.’s stocks have been trading down by -14.45 percent, impacted by concerns over market volatility.

Healthcare industry expert:

Analyst sentiment – negative

Candel Therapeutics (CADL) presents a precarious market position as revealed by key financial ratios and reports. The company reports a staggering pre-tax profit margin of -58976.1%, coupled with a revenue decline of -100% over both three and five-year periods, elucidating severe financial strain. Their enterprise value stands out at $360.34 million against weak earnings, as evidenced by a cash flow statement revealing negative free cash flow at -$10.38 million and operating cash flow of -$10.24 million. The return on assets at -59.26% and return on equity at -101.05% signal deep inefficiencies, exacerbating concerns about ongoing operational viability.

Technically, Candel’s current stock pattern indicates a neutral to bearish trend. After reaching a high of $5.85, the stock’s closing levels retreat, with a trendline from $5.63 to $5.09 through recent trading sessions. This decline, in conjunction with the preceding secondary offering, positions a consolidation phase between $5.20 and $5.45. Given the weak momentum, traders might consider a short-sell strategy near the support level of $5.20, with tight stops above $5.45, focusing on potential breakdowns amid low buying volume.

Recent developments such as the pricing of an 18.3 million share secondary offering at the lower end signify market skepticism, reflecting on CADL’s need to bolster its financial foundations. Its $100 million stock offering aims to prop up gene therapy commercialization and NSCLC developments. However, these efforts may face headwinds amidst prevailing sectoral challenges. Candel’s ability to stabilize hinges on executing its transitional strategies with precision, yet current performance lags relative to broader Biotech & Life Sciences benchmarks. Consequently, with resistance around $5.45 and possible support at $5.20, we hold a negative outlook on CADL’s medium-term prospects.

  • A significant underwritten common stock offering valued at $100 million has been initiated to further the commercialization pursuits of its leading gene therapy aglatimagene besadenovec. This effort is aimed at addressing early, localized prostate cancer and facilitating advancing developments in a Phase 3 NSCLC study.

Candlestick Chart

Weekly Update Feb 16 – Feb 20, 2026: On Saturday, February 21, 2026 Candel Therapeutics Inc. stock [NASDAQ: CADL] is trending down by -14.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Candel Therapeutics has embarked on a dual initiative by pricing their new share issuance while also launching a broader offering to fund its therapeutic ambitions. The stock price has shown volatility over recent days, reflecting market responses to these financial maneuvers. On February 17, the stock opened and closed at $5.63, but by February 20, it had dipped slightly to $5.09 at closing, suggesting market caution around immediate valuations. The announced stock offerings, essential for capital influx, seem aimed at solidifying their cash position while backing novel therapeutic ventures.

Key financial metrics reveal some challenges. The latest financials highlight a grim picture with negative profitability margins, underscored by extreme pretax profit margin figures far below expected norms, and declining revenue indicators. CADL’s financial ratios reflect significant hurdles: a troublingly high price-to-book ratio, compounded by negative returns on critical assets and capital. These numbers suggest the company is currently operating under notable financial pressure, emphasizing the necessity of their current funding strategy.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”